Ketoconazole Plus Docetaxel to Treat Prostate Cancer

This study has been completed.

Study NCT00032825 Information provided by National Institutes of Health Clinical Center (CC)

First Received: April 3, 2002 Last Updated: December 29, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 2011
Primary Completion Date:	May 2004 (Final data collection date for primary outcome measure)

No publications provided by National Institutes of Health Clinical Center (CC)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD. Estrogen receptor ? and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. Epub 2010 Nov 24.